Remdesivir (COVID-19 treatment)

URI: https://gptkb.org/entity/Remdesivir_(COVID-19_treatment)
GPTKB entity
Statements (34)
Predicate Object
gptkbp:instanceOf antiviral drug
gptkbp:administeredBy intravenous infusion
hospitalized patients with COVID-19
gptkbp:approvedBy gptkb:U.S._Food_and_Drug_Administration
2020
gptkbp:ATCCode J05AB16
gptkbp:brand gptkb:Veklury
gptkbp:chemicalFormula C27H35N6O8P
gptkbp:clinicalTrialPhase gptkb:ACTT-1
gptkb:Solidarity_trial
gptkbp:contraindication severe renal impairment
hypersensitivity to remdesivir
gptkbp:developedBy gptkb:Gilead_Sciences
gptkbp:eliminationHalfLife 1 hour (remdesivir), 25 hours (GS-441524)
gptkbp:excretion gptkb:kidney
gptkbp:firstSynthesized 2014
gptkbp:foundIn gptkb:World_Health_Organization_Model_List_of_Essential_Medicines
https://www.w3.org/2000/01/rdf-schema#label Remdesivir (COVID-19 treatment)
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction RNA polymerase inhibitor
gptkbp:metabolism liver
gptkbp:molecularWeight 602.6 g/mol
gptkbp:patent gptkb:Gilead_Sciences
gptkbp:pregnancyCategory Not assigned (US)
gptkbp:prodrugOf gptkb:GS-441524
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect nausea
elevated liver enzymes
allergic reactions
gptkbp:usedFor gptkb:COVID-19
gptkb:Ebola_virus_disease
gptkbp:WHOStatus conditional recommendation against use in COVID-19
gptkbp:bfsParent gptkb:Gilead
gptkbp:bfsLayer 5